导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.38% | 1087/4773 |
| 近一周 | -2.62% | 2703/5462 |
| 近一月 | -0.82% | 830/5421 |
| 近一季 | -4.02% | 1525/5209 |
| 近半年 | -11.49% | 3735/4920 |
| 近一年 | 21.99% | 359/4366 |
| 近两年 | 74.77% | 890/2954 |
| 近三年 | 64.77% | 377/2253 |
| 成立以来 | 109.08% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
8.35% 117/4961 |
-4.12% 3490/5312 |
- - |
- - |
| 2025 | 47.68% 557/4813 |
0.24% 1934/3635 |
4.14% 851/4076 |
26.95% 1322/4524 |
11.44% 165/4813 |
| 2024 | 12.07% 1275/3463 |
13.82% 14/2808 |
-0.13% 690/3014 |
7.89% 2794/3129 |
-8.62% 2871/3463 |
| 2023 | 4.59% 224/2656 |
7.81% 522/2280 |
-3.17% 750/2385 |
3.65% 177/2515 |
-3.33% 661/2655 |
| 2022 | -4.08% 80/2207 |
1.90% 88/1919 |
4.34% 1021/2016 |
-4.78% 62/2113 |
-5.27% 1923/2208 |
| 2021 | 40.73% 29/1822 |
3.86% 168/1255 |
11.03% 406/1330 |
29.13% 14/1466 |
-5.49% 1513/1822 |
| 2020 | 17.97% 751/1250 |
-14.29% 956/1028 |
2.62% 964/1067 |
10.69% 522/1164 |
21.17% 57/1184 |
| 2019 | 15.50% 693/1092 |
17.23% 659/754 |
-2.58% 358/804 |
-5.22% 788/850 |
6.72% 562/918 |
| 2018 | -30.33% 468/834 |
- - |
- - |
- - |
-15.43% 605/691 |
| 2017 | 19.16% 198/714 |
- - |
- - |
- - |
- - |
| 2016 | -5.30% 173/605 |
- - |
- - |
- - |
- - |
| 2015 | -9.57% 293/575 |
- - |
- - |
- - |
- - |
| 2014 | 29.22% 171/237 |
- - |
- - |
- - |
- - |
| 2013 | -32.56% 178/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 博时上证自然资源ETF联接A VS. 长安沪深300非周期A(740101) |